title: Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays.
abstract: OBJECTIVE
  We assessed the ability of different classes of histone deacetylase inhibitors to target tumor and invasive suppressor genes in a panel of bladder carcinoma cell lines using reverse phase protein arrays.
  
  
  METHODS
  Three poorly, moderately and highly invasive cell lines were exposed to histone deacetylase inhibitors, trichostatin A, apicidin, valproic acid (Sigma) and MS-275 (AXXORA) for 0 to 36 hours. Lysates were harvested and arrayed in a 10-fold dilution series in duplicate. Data points were collected and analyzed using a concentration interpolation methodology after normalization.
  
  
  RESULTS
  Protein expression profiles revealed up-regulation of gamma-catenin in highly invasive lines, and alpha-catenin in moderately and highly invasive lines after exposure to all histone deacetylase inhibitors, apicidin and MS-275, respectively. Gelsolin was up-regulated in poorly and moderately invasive lines after exposure to all histone deacetylase inhibitors. Desmoglein was down-regulated in poorly and moderately invasive cell lines by all 4 histone deacetylase inhibitors, in addition to decreased FAK (Transduction Laboratories) expression in moderately and highly invasive lines exposed to valproic acid and MS-275.
  
  
  CONCLUSIONS
  Different histone deacetylase inhibitor classes have the potential to modulate tumor and invasive suppressor gene expression, identifying histone deacetylase inhibitors as potential therapeutic agents for bladder cancer. Reverse phase protein arrays enable high throughput screening of multiple compounds to assess the expression profile of specific protein groups targeted for therapy.
authors.affiliation: Department of Urology, Burlington, Massachusetts, USA.
authors.forename: Justin J
authors.initials: JJ
authors.lastname: Gould
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Kenney
authors.forename: Kimberly M
authors.initials: KM
authors.lastname: Rieger-Christ
authors.forename: Brasil
authors.initials: B
authors.lastname: Silva Neto
authors.forename: Matthew F
authors.initials: MF
authors.lastname: Wszolek
authors.forename: Amanda
authors.initials: A
authors.lastname: LaVoie
authors.forename: Antonia H
authors.initials: AH
authors.lastname: Holway
authors.forename: Brett
authors.initials: B
authors.lastname: Spurrier
authors.forename: John
authors.initials: J
authors.lastname: Austin
authors.forename: Bernard K
authors.initials: BK
authors.lastname: Cammarata
authors.forename: David
authors.initials: D
authors.lastname: Canes
authors.forename: John A
authors.initials: JA
authors.lastname: Libertino
authors.forename: Ian C
authors.initials: IC
authors.lastname: Summerhayes
mesh_terms: D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D016153:Genes, Suppressor / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D009361:Neoplasm Invasiveness; D040081:Protein Array Analysis; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology*
chemical_list: D056572:Histone Deacetylase Inhibitors